Living Cell Technologies Limited is rated 3 out of 5 in the category biotechnology. Read and write reviews about Living Cell Technologies Limited. LCT is a cell-based biotechnology developing insulin producing porcine pancreatic islets for the treatment of type 1 diabetes . LCT's lead product, DIABECELL is in Phase II clinical trial. LCT's encapsulation technology immunoisolates cells and allows cell implants without the use of immunosuppressive drugs. LCT has a pipeline of of neurotrophin producing cells for Parkinson's disease, Huntington's disease, stroke and Hearing Loss. LCT owns a unique source of high health status pigs suitable as a source of tissue for human therapeutics. LCT invites collaboration and strategic partnerships for the further development of cell therapeutics, cell encapsulation and the use of porcine tissue as a source of biomaterials.
Company size
11-50 employees